Category Filter
- Advanced Imaging
- Autism Spectrum Mandate
- Behavioral Health
- Blue Advantage Policies
- Chronic Condition Management
- Genetic Testing
- HealthSmartRx Smart RxAssist Program
- Hemophilia Drugs
- Medical Policies
- Pre-Service Review (Predetermination/Precertification)
- Provider-Administered Drug Policies
- Radiation Therapy
- Self-Administered Drug Policies
- Transgender Services
Asset Publisher
Adakveo® (crizanlizumab-tmca)
Policy Number: PH-0513
Intravenous
Last Review Date: 01/04/2024
Date of Origin: 12/16/2019
Dates Reviewed: 12/2019, 01/2021, 01/2022, 01/2023, 01/2024
FOR PEEHIP Members Only -Coverage excludes the provider-administered medication(s) outlined in this drug policy from being accessed through a specialty pharmacy. It must be obtained through buy and bill. |
- Length of Authorization
Coverage will be provided for 6 months initially and may be renewed annually thereafter.
- Dosing Limits
A. Quantity Limit (max daily dose) [NDC Unit]:
- Adakveo 100 mg/10 mL single-dose vials: 6 vials at weeks 0 and 2 and every 4 weeks thereafter
B. Max Units (per dose and over time) [HCPS Unit]:
- 120 billable units at weeks 0 and 2 and every 4 weeks thereafter
- Initial Approval Criteria 1
Depending on member benefits, additional criteria may apply for coverage of this drug in an outpatient facility setting. Verify any Site of Service requirements with the member’s plan and refer to the Voluntary Site of Service Policy or the Mandatory Site of Service Policy for additional information. |
Coverage is provided in the following conditions:
- Patient is at least 16 years of age; AND
Universal Criteria
- Therapy will not be used in conjunction with voxelotor (Oxbryta) or L-glutamine (Endari); AND
- Patient has not received prior treatment with gene therapy (i.e., lovotibeglogene autotemcel, exagamglogene autotemcel); OR
- Patient failed to respond or lost response to treatment prior gene therapy (i.e., lovotibeglogene autotemcel, exagamglogene autotemcel); AND
Sickle Cell Disease 1-3 † Ф
- Patient has a confirmed diagnosis of sickle-cell disease, of any genotype (e.g., HbSS, HbSC, HbS/beta0-thalassemia, HbS/beta+-thalassemia, and others) as determined by one of the following:
- Identification of significant quantities of HbS with or without an additional abnormal β-globin chain variant by hemoglobin assay; OR
- Identification of biallelic HBB pathogenic variants where at least one allele is the p.Glu6Val pathogenic variant on molecular genetic testing; AND
- Patient had an insufficient response to a minimum 3-month trial of hydroxyurea (unless contraindicated or intolerant); AND
- Patient experienced one or more vaso-occlusive crises (VOC)* in the previous year despite adherence to hydroxyurea therapy
*VOC is defined as an event prompting either a visit or outreach to the provider which results in a diagnosis of VOC being made necessitating subsequent interventions such as narcotic pain management, non-steroidal anti-inflammatory therapy, hydration, etc.
† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ф Orphan Drug
- Renewal Criteria 1,3
Coverage can be renewed based upon the following criteria:
- Patient continues to meet the universal and other indication-specific relevant criteria identified in section III; AND
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: severe infusion related reactions (e.g., pain in various locations, headache, fever, chills, nausea, vomiting, diarrhea, fatigue, dizziness, pruritus, urticaria, sweating, shortness of breath or wheezing), etc.; AND
- Disease response compared to pretreatment baseline as evidenced by a decrease in the frequency of vaso-occlusive crises (VOC) necessitating treatment, reduction in number or duration of hospitalizations, and/or reduction in severity of VOC
- Dosage/Administration 1
Indication |
Dose |
Sickle-Cell Disease |
Administer 5 mg/kg by intravenous infusion over a period of 30 minutes at Week 0, Week 2, and every 4 weeks thereafter. |
- Billing Code/Availability Information
HCPCS:
- J0791 – Injection, crizanlizumab-tmca, 5 mg; 1 billable unit = 5 mg
NDC:
- Adakveo 100 mg/10 mL (10 mg/mL) single-dose vial: 00078-0883-xx
- References
- Adakveo [package insert]. East Hanover, NJ; Novartis Pharmaceuticals, Inc., September 2022. Accessed December 2023.
- Bender MA, Carlberg K. Sickle Cell Disease. 2003 Sep 15 [Updated 2022 Nov 17]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1377/.
- Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3.
- Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014 Sep 10;312(10):1033-48.
Appendix 1 – Covered Diagnosis Codes
ICD-10 |
ICD-10 Description |
D57.00 |
Hb-SS disease with crisis unspecified |
D57.01 |
Hb-SS disease with acute chest syndrome |
D57.02 |
Hb-SS disease with splenic sequestration |
D57.03 |
Hb-SS disease with cerebral vascular involvement |
D57.04 |
Hb-SS disease with crisis with other specified complication |
D57.1 |
Sickle-cell disease without crisis |
D57.20 |
Sickle-cell/Hb-C disease without crisis |
D57.211 |
Sickle-cell/Hb-C disease with acute chest syndrome |
D57.212 |
Sickle-cell/Hb-C disease with splenic sequestration |
D57.213 |
Sickle-cell/Hb-C disease with cerebral vascular involvement |
D57.214 |
Sickle-cell/Hb-C disease with crisis with other specified complication |
D57.219 |
Sickle-cell/Hb-C disease with crisis unspecified |
D57.3 |
Sickle-cell trait |
D57.40 |
Sickle-cell thalassemia without crisis |
D57.411 |
Sickle-cell thalassemia with acute chest syndrome |
D57.412 |
Sickle-cell thalassemia with splenic sequestration |
D57.413 |
Sickle-cell thalassemia, unspecified, with cerebral vascular involvement |
D57.414 |
Sickle-cell thalassemia, unspecified, with crisis with other specified complication |
D57.419 |
Sickle-cell thalassemia with crisis unspecified |
D47.42 |
Sickle-cell thalassemia beta zero without crisis |
D57.431 |
Sickle-cell thalassemia beta zero with acute chest syndrome |
D57.432 |
Sickle-cell thalassemia beta zero with splenic sequestration |
D57.433 |
Sickle-cell thalassemia beta zero with cerebral vascular involvement |
D57.434 |
Sickle-cell thalassemia beta zero with crisis with other specified complication |
D57.439 |
Sickle-cell thalassemia beta zero with crisis unspecified |
D57.44 |
Sickle-cell thalassemia beta plus without crisis |
D57.451 |
Sickle-cell thalassemia beta plus with acute chest syndrome |
D57.452 |
Sickle-cell thalassemia beta plus with splenic sequestration |
D57.453 |
Sickle-cell thalassemia beta plus with cerebral vascular involvement |
D57.454 |
Sickle-cell thalassemia beta plus with crisis with other specified complication |
D57.459 |
Sickle-cell thalassemia beta plus with crisis unspecified |
D57.80 |
Other sickle-cell disorders without crisis |
D57.811 |
Other sickle-cell disorders with acute chest syndrome |
D57.812 |
Other sickle-cell disorders with splenic sequestration |
D57.813 |
Other sickle-cell disorders with cerebral vascular involvement |
D57.814 |
Other sickle-cell disorders with crisis with other specified complication |
D57.819 |
Other sickle-cell disorders with crisis, unspecified |
Appendix 2 – Centers for Medicare and Medicaid Services (CMS)
The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: https://www.cms.gov/medicare-coverage-database/search.aspx. Additional indications, including any preceding information, may be applied at the discretion of the health plan.
Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A
Medicare Part B Administrative Contractor (MAC) Jurisdictions |
||
Jurisdiction |
Applicable State/US Territory |
Contractor |
E (1) |
CA, HI, NV, AS, GU, CNMI |
Noridian Healthcare Solutions, LLC |
F (2 & 3) |
AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ |
Noridian Healthcare Solutions, LLC |
5 |
KS, NE, IA, MO |
Wisconsin Physicians Service Insurance Corp (WPS) |
6 |
MN, WI, IL |
National Government Services, Inc. (NGS) |
H (4 & 7) |
LA, AR, MS, TX, OK, CO, NM |
Novitas Solutions, Inc. |
8 |
MI, IN |
Wisconsin Physicians Service Insurance Corp (WPS) |
N (9) |
FL, PR, VI |
First Coast Service Options, Inc. |
J (10) |
TN, GA, AL |
Palmetto GBA, LLC |
M (11) |
NC, SC, WV, VA (excluding below) |
Palmetto GBA, LLC |
L (12) |
DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA) |
Novitas Solutions, Inc. |
K (13 & 14) |
NY, CT, MA, RI, VT, ME, NH |
National Government Services, Inc. (NGS) |
15 |
KY, OH
|
CGS Administrators, LLC |